keyword
https://read.qxmd.com/read/38052147/-current-situation-of-direct-oral-anticoagulants-in-primary-care-in-spain-positioning-of-semergen-in-2023
#1
J Polo-García, V Pallares-Carratalá, M Turegano-Yedro, J C Romero-Vigara, M A Prieto-Díaz, S Cinza-Sanjurjo
Oral anticoagulation is the key to reduce the risk of stroke in atrial fibrillation. Although vitaminK antagonists (VKA) have classically been used for this purpose, they have been largely overcome by direct oral anticoagulants (DOAC), as demonstrated by evidence from clinical trials, real-life and population studies. In fact, all clinical practice guidelines recommend their use preferentially over VKA. However, in Spain the prescription of DOAC is subordinated to an inspection visa that includes the clinical conditions defined in the Therapeutic Positioning Report of the Spanish Medicines Agency, and that still imposes important restrictions on their use, limiting the benefits of using DOACs in patients with atrial fibrillation (AF), and also generating inequalities between the different autonomous communities...
December 4, 2023: Semergen
https://read.qxmd.com/read/33308848/oral-anticoagulation-in-chronic-kidney-disease-with-atrial-fibrillation
#2
REVIEW
Pablo Gómez-Fernández, Antonio Martín Santana, Juan de Dios Arjona Barrionuevo
Chronic kidney disease (CKD) and atrial fibrillation (AF) frequently coexist, amplifying the risk of cardiovascular events and mortality. In patients with CKD stage3 and non-valvular AF, direct oral anticoagulants (DOACs) have shown, compared to vitaminK antagonists (VKA), equal or greater efficacy in the prevention of stroke and systemic embolism, and greater safety. There are no randomized trials of the efficacy and safety of DOACs and VKA in advanced CKD. On the other hand, observational studies suggest that DOACs, compared to warfarin, are associated with a lower risk of acute kidney damage and generation/progression of CKD...
2021: Nefrología
https://read.qxmd.com/read/31331766/-use-of-direct-acting-oral-anticoagulants-in-primary-care-in-spain-positioning-statement-by-semergen-on-the-current-situation
#3
REVIEW
J L Llisterri Caro, S Cinza-Sanjurjo, J Polo Garcia, M A Prieto Díaz
The direct-acting oral anticoagulants (DOACs) are drugs that have been shown to have a safety profile superior to the vitaminK antagonists (VKA). The prescribing of DOACs in Spain is subject to approval in the form of an inspection visa. This sets out the clinical conditions defined in the Spanish Medicines Agency Therapeutic Positioning Report (TPR) of 2013, updated in 2016. These recommendations do not coincide with those of the European Cardiology Society (2016), restricting the use of DOACs to a second-line treatment in the majority of cases...
July 19, 2019: Semergen
https://read.qxmd.com/read/31213323/security-profile-of-direct-anticoagulants-preferred-use-in-atrial-fibrillation
#4
JOURNAL ARTICLE
Inmaculada Roldán Rabadán, María Alonso de Leciñana, Raquel Barba Martín, José Antonio Páramo Fernández
A multidisciplinary panel of cardiologists, neurologists, internal medicine and specialists in hemostasis and thrombosis has elaborated this document showing recent scientific evidences supporting a better profile of direct oral anticoagulants (DOACs) versus vitaminK antagonists (VKA), as well as the indications of specific antidotes and hemostatic agents to reverse the anticoagulant effects of DOACs. The analysis reinforces the best profile of DOACs and its special benefit in patients with basal high hemorrhagic risk...
June 15, 2019: Clínica e Investigación en Arteriosclerosis
https://read.qxmd.com/read/29983190/factors-associated-with-poor-anticoagulation-control-with-vitamink-antagonists-among-outpatients-attended-in-internal-medicine-and-neurology-the-aladin-study
#5
JOURNAL ARTICLE
M M Contreras Muruaga, G Reig, J Vivancos, A González, P Cardona, J M Ramírez-Moreno, J Martí-Fábregas, C Suárez Fernández
OBJECTIVE: To identify factors associated with poor anticoagulation control with vitaminK antagonists (VKA) among outpatients with nonvalvular atrial fibrillation (NVAF) attended in Neurology and Internal Medicine in Spain. METHODS: Cross-sectional and multicenter study, from the ALADIN database, of outpatients with NVAF treated with VKA and attended in Internal Medicine and Neurology in Spain. Rates of anticoagulation control were determined with the direct and Rosendaal methods, considering data from the 6months before the inclusion...
October 2018: Revista Clínica Española
https://read.qxmd.com/read/29321366/venous-thromboembolism-associated-with-protein-s-deficiency-due-to-arg451-mutation-in-pros1-gene-a-case-report-and-a-literature-review
#6
JOURNAL ARTICLE
Ewa Wypasek, Marek Karpinski, Martine Alhenc-Gelas, Anetta Undas
Protein S (PS) is a vitaminK-dependent glycoproteinwhich plays an important role in the regulation of blood coagulation. PS deficiency has been found in 1.5-7% of thrombophilic patients. Here, we report the first Polish case with PS deficiency caused by the p.Arg451* in the PROS1 gene detected in a 21-year-old man with trauma-induced venous thromboembolism. To our knowledge, we provided the review of all the available data on this mutation (a total of 56 cases). The proband, his mother and his sister were screened for thrombophilia...
December 2017: Journal of Genetics
https://read.qxmd.com/read/28408116/-prevalence-of-oral-anticoagulation-and-quality-of-its-management-in-primary-healthcare-a-study-by-the-health-sentinel-network-of-the-region-of-valencia-spain
#7
JOURNAL ARTICLE
Ana Boned-Ombuena, Jordi Pérez-Panadés, Aurora López-Maside, Maite Miralles-Espí, Sandra Guardiola Vilarroig, Desamparados Adam Ruiz, Oscar Zurriaga
OBJECTIVE: To estimate the prevalence of patients with oral anticoagulant therapy (OAT) in the Region of Valencia and to evaluate the quality of management of OAT with vitaminK antagonists (VKA) carried out in primary healthcare. DESIGN: Observational cross-sectional study conducted through the Health Sentinel Network of the Region of Valencia, which includes a survey and the retrospective analysis of OAT monitoring. SETTING: Primary healthcare, Region of Valencia, Spain...
November 2017: Atencion Primaria
https://read.qxmd.com/read/26877111/-update-on-the-control-of-patients-on-treatment-with-vitamink-antagonist-oral-anticoagulants-in-primary-care
#8
JOURNAL ARTICLE
P Fernández López, M I López Ramiro, I Merino de Haro, G Cedeño Manzano, F J Díaz Siles, A Hermoso Sabio
BACKGROUND: In Spain, more than 80% of patients with atrial fibrillation (AF) receive oral anticoagulant therapy (OAT), and 72% of these patients are followed up in the Primary Care (PC) setting. Recent studies have shown that there is insufficient control of patients on OAT. The objective of the present study was to obtain more detailed information on the state of control of patients on treatment with vitaminK antagonist (VKA) oral anticoagulants (OAC), on the diseases for which the therapy was indicated and on concomitant diseases...
November 2016: Semergen
https://read.qxmd.com/read/25192579/-progress-of-anticoagulation-therapy-in-atrial-fibrillation
#9
REVIEW
Miguel Hernández Olmedo, Carmen Suárez Fernández
Atrial fibrillation is currently a very prevalent disease and it represents one of the most common causes of disabling stroke. Antithrombotic therapies have reduced the incidence of this complication although they pose many limitations and difficulties. As a result, a large number of high risk patients do not receive an appropriate treatment. In recent years, four new oral anticoagulants (NOAC) with relevant advantages in comparison to vitaminK antagonists have been released. Four large phaseiii clinical trials have demonstrated that NOAC are at least as safe and efficacious as warfarin in stroke prevention in non-valve atrial fibrillation patients with moderate-high thrombotic risk, being their main advantage the reduction in intracranial hemorrhage...
August 7, 2015: Medicina Clínica
https://read.qxmd.com/read/2076430/the-effect-of-oxidizing-agents-on-cell-division-and-shape
#10
JOURNAL ARTICLE
M Tomono, T Urayama
Certain oxidizing agents such as vitaminK(VK) and lipid peroxides were found to suppress an increase in cytoplasmic Ca2+ concentration by growth factors, and inhibit on cell proliferation. These oxidizing agents induced a marked change in cell shape. In a detailed analysis of each phase in the cell cycle, the inhibition of an increase in cytoplasmic Ca2+ and cell division occurred only when the agents were added at G0/G1 phase. The addition to S or M phase cells did not influence in cytoplasmic Ca2+ and cell division...
October 1990: Human Cell
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.